Maria Halasz Share Price Tracker, page-24

I asked her about a timeline for the midkine antibody program. While I did not ask her if I could release the details, I don't see any problem with posting an excerpt:
"With the funds raised we will be able to progress to a pre-IND meeting by completing (human in vitro) tissue cross reactivity and single dose toxicity studies (page 1 of our newsletter). These are significant milestones and go towards de-risking the program. As you point out toxicity is one of the areas we need to address and these will be the first ever formal toxicology studies of our antibody.

We have released the approximate timing of the pre-IND meeting as mid 2015 although it will depend on many factors, some outside of our control, like the FDA. On the other hand, the timing of the clinical trials will depend on availability of funding, manufacturing timetables, clinical facilities etc. Hence it is not possible to commit to a timeline at this stage on this front. "

Overall, the email gave the impression of competence and it was not formulaic. She scored brownie points with me for it.

I'm anticipating shrill cries of derision on this forum in response to this post. I'm not proposing to respond to them or to engage in further correspondence on HC about this or any other matters. For many months I have followed the HC forums without registering or posting. I am going to revert to that policy, because there is way too much name-calling and emoting here and the moderation is used like a blunt instrument. Cheers.